VYVGART was well-tolerated with a safety profile consistent with the established profile of VYVGART in patients with AChR-Ab seropositive gMG and other indications. No new safety concerns were ...
Ribupatide (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg ...
European Commission approves Sanofi’s Teizeild to treat patients with stage 2 type 1 diabetes: Paris Tuesday, January 13, 2026, 11:00 Hrs [IST] The European Commission has appro ...
Quince Therapeutics (QNCX) rated Buy ahead of Phase 3 NEAT readout in A-T; eDSP targets $1B+ orphan market with strong cash ...
ScienceAlert on MSN
Caffeine in Your Blood Might Affect Body Fat And Diabetes Risk, Study Shows
The levels of caffeine in your blood could affect the amount of body fat you carry, a factor that in turn could determine ...
Breaking down the new 2025-2030 U.S. Dietary Guidelines: why the new recommendation is to "consume less alcohol for better ...
Clinical research technology veteran joins to accelerate company's growth as the unified platform solution for ...
Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetesApproval based on the TN-10 phase 2 study that demonstrated a ...
MedPage Today on MSN
Sleep, Women, and Tau; Prenatal COVID and the Brain; Why FDA Rejected MS Drug
A prospective study of 39 mother-infant dyads exposed to SARS-CoV-2 during pregnancy suggested that cognitive skills in ...
In this phase 3 trial, researchers aimed to study the efficacy of tumor bed boost and moderately hypofractionated whole breast irradiation in patients with non-low-risk DCIS.
A new study provides novel insights into the durability of endovascular thrombectomy in patients with stroke caused by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback